0001367644-26-000051
SEC filingEmergent BioSolutions held its 2026 annual meeting on April 29, 2026, where stockholders approved the amendment to its Amended and Restated Stock Incentive Plan to increase the share reserve by 5,000,000 shares and ratified Ernst & Young LLP as auditor.
The 2026 annual meeting resulted in the approval of four key proposals, most notably the amendment to the Stock Incentive Plan — a material equity grant expansion that adds 5 million shares to the reserve, bringing the total to 36,208,561. While approved, Proposal 4 received only 54.7% support among votes cast (excluding broker non-votes), signaling notable stockholder skepticism about dilution and compensation design. Similarly, the advisory vote on 2025 executive compensation passed with just 60.3% support among votes cast, suggesting ongoing governance concerns regarding pay-for-performance alignment. Director elections showed relatively low withhold rates for John Fowler, Jr. (1.3%) but higher rates for Zsolt Harsanyi (7.9%), potentially reflecting differentiated views on board composition. The strong ratification of Ernst & Young (96.8% of votes cast) indicates consensus on audit oversight. Collectively, these outcomes highlight active stockholder engagement on governance and equity practices, with implications for future say-on-pay and equity plan renewals.